Drug Trial Radar · NCT06005441
A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.
Last checked: Nov 19, 2026Latest source record: Dec 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
173
Actual
Start
Nov 10, 2023
Primary completion
Oct 18, 2024
Study completion Oct 18, 2024
Sponsor
- Lead sponsor
- Caliway Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, placebo-controlled, Phase 2b study to evaluate the efficacy, safety, and tolerability of CBL-514 injection compared with CBL-A1 and CBL-A2 for reducing subcutaneous fat.
Conditions
- Subcutaneous Fat
Interventions
CBL-514 injectionDrug
Provided as a ready for use injectable CBL-514 solution
CBL-A1 InjectionDrug
Provided as a ready for use injectable CBL-A1 solution
CBL-A2 InjectionDrug
Provided as a ready for use injectable CBL-A2 solution
0.9% Sodium ChlorideDrug
Sodium Chloride (0.9% NaCl) placebo for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with at least 20% subcutaneous fat change compared to Baseline, of CBL-514 compared with placeboTime frame: From Baseline to 4 weeks after the final treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigational Site 1
Omaha, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.